Body Protection Compound — Pentadecapeptide
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid pentadecapeptide derived from a protective protein found in human gastric juice. First isolated and characterized by Predrag Sikiric and colleagues at the University of Zagreb, Croatia, BPC-157 has been the subject of over 100 published preclinical studies since the early 1990s. The peptide is a partial sequence of the larger body protection compound (BPC), a protein naturally present in gastric secretions that plays a role in maintaining GI mucosal integrity. BPC-157 has demonstrated remarkable tissue repair activity across virtually every tissue type studied — including tendons, ligaments, skeletal muscle, bone, intestinal mucosa, corneal tissue, nerve tissue, and vascular endothelium. This broad-spectrum cytoprotective activity is unique among research peptides and is attributed to its ability to modulate multiple growth factor pathways simultaneously, including VEGF, FGF, EGF, and the nitric oxide (NO) system. A distinguishing feature of BPC-157 is its stability in human gastric juice — unlike most peptides, it is not degraded by digestive enzymes, which has led to research on both systemic (subcutaneous) and oral administration routes. This gastric stability is biologically logical given its origin as a gastric juice protein fragment and has practical implications for research protocol design.
Demonstrated repair activity across tendon, ligament, muscle, bone, GI, nerve, and vascular tissue in over 100 preclinical studies.
Upregulates VEGF signaling to accelerate blood vessel formation at injury sites, improving nutrient and oxygen delivery.
Protects and repairs gastric and intestinal mucosa, with demonstrated efficacy against NSAID-induced gastropathy, IBD models, and esophageal damage.
Preclinical models show nerve regeneration, neuroprotection against toxins, and modulation of the dopamine and serotonin systems.
Accelerated healing of transected Achilles tendon, medial collateral ligament, and quadriceps tendon in rat models.
Uniquely stable in acidic gastric conditions, enabling both systemic (SC) and oral administration for research purposes.
Modulates inflammatory cascades including TNF-alpha, IL-6, and prostaglandin pathways without immunosuppressive effects.
Interacts with the nitric oxide system to maintain endothelial function and vascular tone during injury and repair.
BPC-157 operates through a complex network of growth factor modulation rather than a single receptor-ligand interaction. The primary mechanism involves upregulation of vascular endothelial growth factor (VEGF) signaling, which promotes angiogenesis — the formation of new blood vessels from pre-existing vasculature. This neovascularization is critical for tissue repair as it delivers oxygen, nutrients, and immune cells to injury sites. Simultaneously, BPC-157 modulates the nitric oxide (NO) system through interactions with both the constitutive (eNOS) and inducible (iNOS) nitric oxide synthase pathways. In conditions of NO depletion, BPC-157 compensates through eNOS upregulation; in NO excess (as seen in inflammation), it provides a counterbalancing effect. This bidirectional NO modulation is believed to underlie its vascular protective properties and its ability to normalize blood pressure in both hypertensive and hypotensive models. BPC-157 also modulates fibroblast growth factor (FGF), epidermal growth factor (EGF), and transforming growth factor beta (TGF-β) signaling. In tendon and ligament models, BPC-157 increases the expression of growth hormone receptor (GHR) and promotes collagen organization — tendon fiber alignment and tensile strength recovery occur at accelerated rates compared to controls. Additionally, BPC-157 has been shown to modulate the FAK-paxillin pathway involved in cell adhesion and migration, and to interact with the dopaminergic system centrally, which may explain observed effects on behavioral models of depression and cognitive performance.
Accelerated healing of transected Achilles tendon, MCL, and quadriceps tendon with improved collagen organization in rat models.
PreclinicalProtection against NSAID gastropathy, alcohol-induced gastric lesions, IBD models, and esophageal damage in multiple animal studies.
PreclinicalEnhanced sciatic nerve regeneration, improved motor and sensory recovery following crush and transection injuries.
PreclinicalAccelerated recovery of crushed and transected skeletal muscle with improved functional outcomes in rat models.
PreclinicalEnhanced bone healing in segmental defect models with improved callus formation and mineralization.
PreclinicalModulation of CNS dopamine and serotonin systems from a gut-derived peptide — studying bidirectional brain-gut signaling.
Preclinical| Period | Dose | Frequency | Notes |
|---|---|---|---|
| 1–4 | 250 mcg | 1–2× daily (SC) | Standard research starting dose — may administer near injury site |
| 5–8 | 500 mcg | 1–2× daily (SC) | Moderate dose for extended protocols |
| 9–12 | 500 mcg–1 mg | 1–2× daily (SC) | Higher dose range for advanced research — assess response |
BPC-157 is uniquely stable in gastric acid, unlike most peptides. Preclinical research has demonstrated efficacy via both subcutaneous injection and oral administration. For systemic tissue repair research (tendons, muscle, bone), subcutaneous injection near the site of interest is most commonly used. For gastrointestinal research (IBD, gastric ulcer models), oral administration is often preferred as it delivers the peptide directly to the target tissue.
BPC-157 is a 15-amino-acid gastric peptide that works primarily through VEGF/NO/growth factor modulation to promote angiogenesis and tissue repair. TB-500 (Thymosin Beta-4) is a 43-amino-acid peptide that works through G-actin sequestration to enable cell migration and blood vessel formation. They operate through distinct mechanisms and are sometimes studied in combination for multi-pathway repair research, as seen in the GLOW and KLOW blends.
BPC-157 has over 100 published preclinical studies demonstrating tissue repair across multiple organ systems. However, no published human clinical trials exist as of 2025. All efficacy data comes from animal models (primarily rats). The breadth and consistency of preclinical evidence is exceptional, but human data remains absent — this is an important limitation for research interpretation.
Reconstitute lyophilized BPC-157 with bacteriostatic water at 2.5 mg/mL (e.g., 2 mL BAC water for a 5 mg vial). Inject water slowly against the vial wall, swirl gently. The solution should be clear. Store at 2–8°C and use within 21 days. Unlike GHK-Cu, BPC-157 is compatible with bacteriostatic water — benzyl alcohol does not interfere with its activity.
Preclinical studies specifically demonstrate that BPC-157 counteracts NSAID-induced gastrointestinal damage, suggesting a protective rather than conflicting interaction. However, BPC-157's effects on angiogenesis and growth factor signaling could theoretically interact with anti-angiogenic medications. No clinical drug interaction studies exist. Research protocols involving concomitant medications should account for potential pathway overlap.
Subcutaneous injection near the injury site theoretically provides higher local peptide concentration at the target tissue. However, preclinical data shows systemic effects even with injection distant from the injury — BPC-157 promotes angiogenesis and modulates NO systemically. For GI targets, oral administration delivers BPC-157 directly to the mucosa. The choice of injection site depends on the specific research question being addressed.
Need help choosing a peptide?
Try the AI Coach →